賀爾蒙治療在復發或晚期子宮內膜癌的角色

Hormonal therapy for advanced or recurrent endometrial cancers

雖然標準治療子宮內膜癌的方法，主要以手術為主。術後，根據必要性再輔以放射線或化學抗癌藥物的治療。傳統上，賀爾蒙用在第一線的子宮內膜癌治療的角色，並不明顯，除非用在非常年輕的婦女且僅侷限於非常早期且分化良好的子宮內膜癌外且其有保留生育的必要時，才會想到使用賀爾蒙來治療子宮內膜癌。所以關於賀爾蒙在子宮內膜癌的治療上的角色，相當於極端，不是非常早期要保留子供者，並是非常晚期或復發的案例，在臨床上，似乎在藥石罔效時，才被考慮到。本文就針對這部分來作討論。

The gold standard treatment of the endometrial cancer is a completely staged surgery, then followed by radiation or chemotherapy, based on final pathological-surgical stage and patient-tailed treatment. In the primary treatment of endometrial cancers, hormones are rarely taken into consideration after primary surgery. Primary treatment with hormones to preserve fertility in younger women with endometrial cancer is attractive, since many successful cases have been reported previously, although majority of them finally received definite therapy, including total hysterectomy. The role of hormone therapy is often delayed to recurrent diseases. For example, response rates to progestins and tamoxifen or aromatase inhibitors in advanced/recurrent endometrial cancers approximate 15~20% and nearly 10% or below, respectively.
This review will be focused on updated information and recent knowledge of the use of hormones in the management of women with advanced or recurrent endometrial cancers.